Evidence map›Paper›PMID 41329905›Full record

ArticleNeurology2025

Physical and Cognitive Activities and Trajectories of AD Neuroimaging Biomarkers: Longitudinal Analysis in the Mayo Clinic Study of Aging.

Janina Krell-Roesch, Jeremy A Syrjanen, Allison L Hansen, Prashanthi Vemuri, Eugene L Scharf, Julie A Fields, Walter K Kremers, Val J Lowe, Jonathan Graff-Radford, Clifford R Jack and 5 more

Abstract read
In one paragraph

Article in Neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Janina Krell-RoeschInstitute of Sports and Sports Science, Karlsruhe Institute of Technology, Germany.ORCID 0000-0003-4011-9842
Jeremy A SyrjanenDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN.
Allison L HansenDepartment of Radiology, Creighton University School of Medicine, Phoenix, AZ.
Prashanthi VemuriDepartment of Radiology, Mayo Clinic, Rochester, MN.ORCID 0000-0003-4286-0589
Eugene L ScharfDepartment of Neurology, Mayo Clinic, Rochester MN.ORCID 0000-0003-2928-3924
Julie A FieldsDepartment of Psychiatry and Psychology, Mayo Clinic, Rochester, MN.ORCID 0000-0002-1282-9866
Walter K KremersDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN.ORCID 0000-0001-5714-3473
Val J LoweDepartment of Radiology, Mayo Clinic, Rochester, MN.ORCID 0000-0002-5612-1667
Jonathan Graff-RadfordDepartment of Neurology, Mayo Clinic, Rochester MN.ORCID 0000-0003-2770-0691
Clifford R JackDepartment of Radiology, Mayo Clinic, Rochester, MN.ORCID 0000-0001-7916-622X
Ronald C PetersenDepartment of Neurology, Mayo Clinic, Rochester MN.ORCID 0000-0002-8178-6601
Susan B RacetteCollege of Health Solutions, Arizona State University, Phoenix; and.ORCID 0000-0002-6932-1887
Alexander WollInstitute of Sports and Sports Science, Karlsruhe Institute of Technology, Germany.
Maria VassilakiDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN.ORCID 0000-0001-8328-136X
Yonas E GedaDepartment of Neurology and the Franke Barrow Global Neuroscience Education Center, Barrow Neurological Institute, Phoenix, AZ.ORCID 0000-0003-1187-7230

Funding

SUPPLEMENT TO ALZHEIMERS DISEASE PATIENT REGISTRYU01AG006786 · NIA · MAYO CLINIC ROCHESTER · PI GRAFF-RADFORD, JONATHAN, JACK, CLIFFORD R. · 1986 to 2023
$49.6M
Research Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI Pamela J McLean · 2019 to 2026
$33.5M
Disease pathways in the population determined by amyloid, tau, and neurodegeneration imaging biomarkersR37AG011378 · NIA · MAYO CLINIC ROCHESTER · PI CLIFFORD R. JACK · 2018 to 2026
$6.8M
Validating the New Criteria for Preclinical Alzheimer's diseaseR01AG041851 · NIA · MAYO CLINIC ROCHESTER · PI JACK, CLIFFORD R., KNOPMAN, DAVID S · 2012 to 2021
$6.3M
Development, Validation, and Application of an Imaging based CVD ScaleR01NS097495 · NINDS · MAYO CLINIC ROCHESTER · PI VEMURI, PRASHANTHI · 2016 to 2020
$2.9M
Interdisciplinary Infrastructure for Aging Research: Rochester Epidemiology ProjectR33AG058738 · NIA · MAYO CLINIC ROCHESTER · PI LEBRASSEUR, NATHAN K, OLSON, JANET E · 2020 to 2022
$2.4M
Pathways linking neuropsychiatric symptoms with Alzheimer's disease neuroimaging biomarkers and the outcome of incident Mild Cognitive Impairment/ DementiaR01AG057708 · NIA · ST. JOSEPH'S HOSPITAL AND MEDICAL CENTER · PI GEDA, YONAS E · 2018 to 2022
$1.7M
Interdisciplinary Infrastructure for Aging Research: Rochester Epidemiology ProjectR21AG058738 · NIA · MAYO CLINIC ROCHESTER · PI LEBRASSEUR, NATHAN K, OLSON, JANET E · 2018 to 2019
$437k
NIA NIH HHS P30 AG062677NIA NIH HHS R01 AG041851NIA NIH HHS R01 AG057708NIA NIH HHS R21 AG058738NIA NIH HHS R33 AG058738NIA NIH HHS R37 AG011378NIA NIH HHS U01 AG006786NINDS NIH HHS R01 NS097495
6 · The paper itself

Abstract

BACKGROUND AND

objectivesEngagement in physical and cognitive activities is associated with a decreased risk of mild cognitive impairment (MCI) and dementia, but the association with Alzheimer disease (AD) neuroimaging biomarkers is less clear. We thus examined associations of physical and cognitive activities with longitudinal trajectories of AD neuroimaging biomarkers among older adults free of dementia.

methodsWe conducted a longitudinal study within the population-based Mayo Clinic Study of Aging (mean follow-up durations 1.3-3.4 years). Participants were aged 50 years or older and were cognitively unimpaired or had MCI at baseline. Engagement in physical and cognitive activities during 12 months before baseline was assessed through questionnaires. Participants underwent AD neuroimaging biomarker assessments at 1 or more time points. We ran linear mixed-effect models to examine associations between physical and cognitive activity composite scores and trajectories of individual yearly change in amyloid deposition (Pittsburgh compound B [PiB]-PET centiloid), tau burden (tau-PET standardized uptake value ratio [SUVR]), and regional glucose hypometabolism (fluorodeoxyglucose [FDG]-PET SUVR), adjusted for age, sex,

resultsWe included 1,176 participants (47% female; mean [SD] age, 68.7 [9.6] years) for PiB-PET trajectories, 399 participants (49% female; mean [SD] age, 71.9 [11.0] years) for tau-PET trajectories, and 983 participants (46% female; mean [SD] age, 67.9 [9.2] years) for FDG-PET trajectories. PiB-PET and tau-PET measures increased during follow-up (3.4 [SD 4.0] and 1.3 [SD 2.1] years, respectively), whereas FDG-PET values decreased over 2.9 (SD 3.5) years of follow-up. Participants with higher total physical activity (interaction estimate 0.0017; 95% CI 0.0003-0.0031; DISCUSSION: Physical activity was associated with less synaptic dysfunction and cognitive activity with less synaptic dysfunction and lower amyloid burden over time, albeit effect sizes were small. Further research is needed to validate findings and clarify causal inference between physical and cognitive activities and AD neuroimaging biomarkers.

Indexed as

AgingAlzheimer DiseaseBrainCognitionCognitive DysfunctionAgedAged, 80 and overAniline CompoundsBiomarkersFemaleFluorodeoxyglucose F18HumansLongitudinal StudiesMaleMiddle AgedNeuroimaging2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazoleAniline CompoundsBiomarkersFluorodeoxyglucose F18tau ProteinsThiazoles

Identifiers

PMID41329905
PMCPMC13083612

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.